A potent mitotic inhibitor
Related Products
Active Metabolite(s)
207417-epi Paclitaxel
Labeled Version(s)
22092Paclitaxel-d5
Metabolite(s)
100090276α-hydroxy Paclitaxel
Pro-drug Form(s)
28635Paclitaxel octadecanedioate
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Paclitaxel

Item No. 10461

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
βS-(benzoylamino)-αR-hydroxy-benzenepropanoic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester
CAS Number
33069-62-4
Synonyms
  • NSC 125973
Molecular Formula
C47H51NO14
Formula Weight
853.9
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlDMSO:PBS (pH 7.2) (1:10): 0.1 mg/mlEthanol: 1.5 mg/ml
λmax
228 nm
SMILES
O=C([C@H](OC(C)=O)C1=C(C)[C@@H](OC([C@H](O)[C@@H](NC(C2=CC=CC=C2)=O)C3=CC=CC=C3)=O)C[C@]([C@H]4OC(C5=CC=CC=C5)=O)(O)C1(C)C)[C@@]6(C)[C@@]4([H])[C@@]7(OC(C)=O)[C@H](OC7)C[C@@H]6O
InChi Code
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChi Key
RCINICONZNJXQF-MZXODVADSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $39

    Add

    25 mg

    $106

    Add

    50 mg

    $193

    Add

    100 mg

    $308

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Paclitaxel, a potent disruptor of microtubules derived from the bark of the Pacific yew tree, is widely used as a chemotherapeutic compound. Tested against a panel of cervical (HeLa), lung (A549), breast (MCF-7), colon (HT-29), ovarian (OVG-1), and pancreatic (PC-Sh) carcinomas, paclitaxel demonstrates IC50 values ranging from 2.5-7.5 nM.1 Paclitaxel disrupts multipolar spindle formation, inducing cell cycle arrest in various human cell cancer lines (IC50s = 6.7-18.5 nM) at both prophase and G1.2 It initiates apoptosis of cancer cells through multiple mechanisms involving p53-dependent and -independent pathways, Bcl-2 family members, cyclin-dependent kinases, and c-Jun N-terminal kinases/stress-activated protein kinases.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Liebmann, J.E., Cook, J.A., Lipschultz, C., et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br. J. Cancer 68(6), 1104-1109 (1993).

    2. Woods, C.M., Zhu, J., McQueney, P.A., et al. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1(5), 506-526 (1995).

    3. Wang, T.h., Wang, H.S., and Soong, Y.K. Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer 88(11), 2619-2628 (2000).

    Product Citations

    Kremer, D.M., Nelson, B.S., Lin, L., et al. GOT1 inhibition primes pancreatic cancer for ferroptosis through the autophagic release of labile iron. bioRxiv (2020).

    Huang, J.J., Corona, A.L., Dunn, B.P., et al. Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. Oncogene 38(18), 3402-3414 (2019).